<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Methadone at tapered doses for the management of opioid withdrawal - Amato, L - 2013 | Cochrane Library</title> <meta content="Methadone at tapered doses for the management of opioid withdrawal - Amato, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003409.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Methadone at tapered doses for the management of opioid withdrawal - Amato, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003409.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003409.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Methadone at tapered doses for the management of opioid withdrawal" name="citation_title"/> <meta content="Laura Amato" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="l.amato@deplazio.it" name="citation_author_email"/> <meta content="Marina Davoli" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Silvia Minozzi" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Eliana Ferroni" name="citation_author"/> <meta content="Public Health Agency of Lazio Region" name="citation_author_institution"/> <meta content="Robert Ali" name="citation_author"/> <meta content="University of Adelaide" name="citation_author_institution"/> <meta content="Marica Ferri" name="citation_author"/> <meta content="European Monitoring Centre for Drugs and Drug Addiction" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003409.pub4" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003409.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003409.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003409.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Methadone [*administration &amp; dosage]; Narcotics [*administration &amp; dosage, adverse effects]; Opiate Substitution Treatment [*methods]; Opioid‐Related Disorders [*rehabilitation]; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome [*rehabilitation]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003409.pub4&amp;doi=10.1002/14651858.CD003409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003409\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003409\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003409.pub4",title:"Methadone at tapered doses for the management of opioid withdrawal",firstPublishedDate:"Feb 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003409.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003409.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003409.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003409.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003409.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003409.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003409.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003409.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003409.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003409.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6312 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003409.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/appendices#CD003409-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/table_n/CD003409StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/table_n/CD003409StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Methadone at tapered doses for the management of opioid withdrawal</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Laura Amato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0003">Marina Davoli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0004">Silvia Minozzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0005">Eliana Ferroni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0006">Robert Ali</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information#CD003409-cr-0007">Marica Ferri</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information/en#CD003409-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003409.pub4">https://doi.org/10.1002/14651858.CD003409.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003409-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003409-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003409-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003409-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003409-abs-0001" lang="en"> <section id="CD003409-sec-0001"> <h3 class="title" id="CD003409-sec-0001">Background</h3> <p>The evidence of tapered methadone's efficacy in managing opioid withdrawal has been systematically evaluated in the previous version of this review that needs to be updated </p> </section> <section id="CD003409-sec-0002"> <h3 class="title" id="CD003409-sec-0002">Objectives</h3> <p>To evaluate the effectiveness of tapered methadone compared with other detoxification treatments and placebo in managing opioid withdrawal on completion of detoxification and relapse rate. </p> </section> <section id="CD003409-sec-0003"> <h3 class="title" id="CD003409-sec-0003">Search methods</h3> <p>We searched: Cochrane Central Register of Controlled Trials (<i>The Cochrane Library</i> 2012, Issue 4), PubMed (January 1966 to May 2012), EMBASE (January 1988 to May 2012), CINAHL (2003‐ December 2007), PsycINFO (January 1985 to December 2004), reference lists of articles. </p> </section> <section id="CD003409-sec-0004"> <h3 class="title" id="CD003409-sec-0004">Selection criteria</h3> <p>All randomised controlled trials that focused on the use of tapered methadone versus all other pharmacological detoxification treatments or placebo for the treatment of opiate withdrawal. </p> </section> <section id="CD003409-sec-0005"> <h3 class="title" id="CD003409-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed the included studies. Any doubts about how to rate the studies were resolved by discussion with a third review author. Study quality was assessed according to the criteria indicated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD003409-sec-0006"> <h3 class="title" id="CD003409-sec-0006">Main results</h3> <p>Twenty‐three trials involving 2467 people were included. Comparing methadone versus any other pharmacological treatment, we observed no clinical difference between the two treatments in terms of completion of treatment, 16 studies 1381 participants, risk ratio (RR) 1.08 (95% confidence interval (CI) 0.97 to 1.21); number of participants abstinent at follow‐up, three studies, 386 participants RR 0.98 (95% CI 0.70 to 1.37); degree of discomfort for withdrawal symptoms and adverse events, although it was impossible to pool data for the last two outcomes. These results were confirmed also when we considered the single comparisons: methadone with: adrenergic agonists (11 studies), other opioid agonists (eight studies), anxiolytic (two studies), paiduyangsheng (one study). Comparing methadone with placebo (two studies) more severe withdrawal and more drop‐outs were found in the placebo group. <br/> <br/> The results indicate that the medications used in the included studies are similar in terms of overall effectiveness, although symptoms experienced by participants differed according to the medication used and the program adopted. </p> </section> <section id="CD003409-sec-0007"> <h3 class="title" id="CD003409-sec-0007">Authors' conclusions</h3> <p>Data from literature are hardly comparable; programs vary widely with regard to the assessment of outcome measures, impairing the application of meta‐analysis. The studies included in this review confirm that slow tapering with temporary substitution of long‐ acting opioids, can reduce withdrawal severity. Nevertheless, the majority of patients relapsed to heroin use. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003409-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003409-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003409-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003409-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003409-abs-0003" lang="en"> <h3>Methadone at tapered doses for the management of opioid withdrawal</h3> <p>Abuse of opioid drugs and dependence on them causes major health and social issues that include transmission of HIV and hepatitis C with injection, increased crime and costs for health care and law enforcement, family disruption and lost productivity. Addicts, particularly those aged 15 to 34 years, are also at higher risk of death. Managed withdrawal (or detoxification) is used as the first step in treatment. Withdrawal symptoms include anxiety, chills, muscle pain (myalgia) and weakness, tremor, lethargy and drowsiness, restlessness and irritability, nausea and vomiting and diarrhoea. Persisting sleep disturbances and drug craving can continue for weeks and months after detoxification and often lead to a return to opioid use. The number of addicts who complete detoxification tends to be low, and rates of relapse are high. <br/> <br/> For a tapered dose treatment to reduce withdrawal symptoms, illicit opioids are replaced by methadone or another agent using decreasing doses up to 30 days under medical supervision. The review authors searched the medical literature and identified 23 controlled trials involving 2467 adult opioid users in various countries. Trial participants were randomised to receive methadone or another pharmacological treatment. The other treatments were adrenergic agonists such as lofexidine, partial opioid agonists such as buprenorphine, opioid agonists such as LAAM (levo‐α‐acetyl‐methadol) and the anxiolytics chlordiazepoxide and buspirone. In the two studies that compared methadone with placebo, withdrawal symptoms were more severe and more people dropped out in the placebo group. </p> <p>The studies included in this review confirmed that slow tapering with temporary substitution of long‐ acting opioids, could reduce withdrawal severity. Nevertheless, the majority of patients relapsed to heroin use. The medications used in the included studies were similar in terms of overall effectiveness, although symptoms experienced by participants differed according to the medication used and the program adopted. </p> <p>The programs varied widely with regard to the assessment of outcome measures. Seventeen of the included trials were conducted in inpatient settings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003409-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003409-sec-0083"></div> <h3 class="title" id="CD003409-sec-0084">Implications for practice</h3> <section id="CD003409-sec-0084"> <p>The results indicate that tapered methadone and the other substances used in the included studies are effective in the treatment of heroin withdrawal syndrome, although symptoms presented by participants differed according to the drug used. The studies confirm the issue that with the increasing availability of substances that allow slow tapering and temporary substitution of long‐acting narcotics, with good medical supervision and ancillary medications for tranquillisation and sleep, withdrawal can be relatively painless. Managed withdrawal, or detoxification, is not in itself a treatment for dependence but detoxification remains a required first step for many forms of longer‐term treatment. Moreover, different conditions of detoxification can affect at least an immediate outcome: heroin use during treatment and produce different responses in terms of intensity and time course of withdrawal response. <br/> <br/> Nevertheless, a majority of patients relapsed in heroin use, and relapse from the drug‐free state to re‐addiction is the main problem in heroin addiction. </p> <p>Research suggests that for some important outcomes such as withdrawal symptoms, treatment programs are difficult to compare due to the variability of the methods used to assess them. Withdrawal limited to 30 days has the disadvantage that many persons, due to the rapid tapering, are prematurely withdrawn and consequently resume heroin use. <br/> <br/> There has been a general pessimism among both clinicians and researchers about the utility of brief detoxification treatment because many patients soon returned to regular heroin use. This pessimism is probably based on the unrealistic expectation that a brief, inexpensive intervention could dramatically alter the course of a chronic, relapsing disorder such as heroin addiction. Whether people relapse to heroin use again has no bearing on the success or otherwise of a detoxification procedure and the investment in methadone detoxification could be justified if more modest goals were being achieved for example, the reduction, even temporarily, of the daily heroin dosage, with its consequent reduction of dependence on illegal income and the possibility of reaching drug addicts who would otherwise not have applied for treatment. </p> </section> <h3 class="title" id="CD003409-sec-0085">Implications for research</h3> <section id="CD003409-sec-0085"> <p>To enable comparison and pooling of results, standardised criteria for reporting urinalysis results should be used, data should be reported as number of participants with positive or negative samples instead of mean number of positive/negative tests for each group. When different rating instruments are used, researchers should try to utilise only published instruments, indicate the scores to represent boundaries of mild, moderate and severe withdrawal to allow comparison of results between studies and report the standard deviation of the means. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003409-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003409-sec-0015"></div> <div class="table" id="CD003409-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tapered methadone versus any other treatment for the management of opioid withdrawal</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tapered methadone versus any other treatment for the management of opioid withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with the management of opioid withdrawal <br/> <b>Settings:</b> Inpatient and outpatient <br/> <b>Intervention:</b> Tapered methadone versus any other treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tapered methadone versus any other treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Completion of treatment</b> <br/> Objective <br/> Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.08</b> <br/> (0.97 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1381 <br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> <br/> (531 to 662) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> <br/> (490 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants abstinent at follow‐up</b> <br/> Objective <br/> Follow‐up: mean 1.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.7 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>386 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> <br/> (179 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>262 per 1000</b> <br/> (187 to 366) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003409-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003409-sec-0016"></div> <section id="CD003409-sec-0017"> <h3 class="title" id="CD003409-sec-0017">Description of the condition</h3> <p>Recent figures for illicit drug use indicate that the prevalence of opiate abuse among persons from 15 to 64 years old is around 0.5% in most Western countries (EU, USA, Canada and Australia) (<a href="./references#CD003409-bbs2-0118" title="UNODC, World Drug Report, 2011. Retrieved May 18, 2012, from the United Nation Office on Drug and Crime  web site at: http://www.unodc.org. ">UNODC 2011</a>). Opioid dependence is a worldwide health problem that has enormous economic, personal and public health consequences. There are an estimated 15.6 million illicit opioid users in the world, of whom 11 million use heroin (<a href="./references#CD003409-bbs2-0118" title="UNODC, World Drug Report, 2011. Retrieved May 18, 2012, from the United Nation Office on Drug and Crime  web site at: http://www.unodc.org. ">UNODC 2011</a>). Opioids are the main drugs of abuse in Asia, Europe and much of Oceania, and it is estimated that globally the consumption of the opioid class of drugs is increasing (<a href="./references#CD003409-bbs2-0118" title="UNODC, World Drug Report, 2011. Retrieved May 18, 2012, from the United Nation Office on Drug and Crime  web site at: http://www.unodc.org. ">UNODC 2011</a>). </p> <p>In Europe heroin is still one of the main illegal substance recorded in indicators of problem drug use (<a href="./references#CD003409-bbs2-0100" title="European Monitoring Centre for Drugs and Drug Addiction Annual report 2011: the state of the drugs problem in EuropeLuxembourg. Publications Office of the European Union, available at www.emcdda.europa.eu. [DOI: 10.2810/44330] ">EMCDDA 2011</a>). Recent national estimates vary between one and eight cases per 1000 population aged 15–64 (<a href="./references#CD003409-bbs2-0100" title="European Monitoring Centre for Drugs and Drug Addiction Annual report 2011: the state of the drugs problem in EuropeLuxembourg. Publications Office of the European Union, available at www.emcdda.europa.eu. [DOI: 10.2810/44330] ">EMCDDA 2011</a>). The average prevalence of problem opioid use in the European Union and Norway, computed from national studies, is estimated to be between 3.6 and 4.4 cases per 1000 population aged 15–64 (<a href="./references#CD003409-bbs2-0100" title="European Monitoring Centre for Drugs and Drug Addiction Annual report 2011: the state of the drugs problem in EuropeLuxembourg. Publications Office of the European Union, available at www.emcdda.europa.eu. [DOI: 10.2810/44330] ">EMCDDA 2011</a>). The latest US data, show that, on average, three persons per 100 annual drug users had to undergo treatment for drug use in 2008. Opiates use is far more problematic than the use of other illicit drugs (<a href="./references#CD003409-bbs2-0118" title="UNODC, World Drug Report, 2011. Retrieved May 18, 2012, from the United Nation Office on Drug and Crime  web site at: http://www.unodc.org. ">UNODC 2011</a>). Australia has an estimated 67,000–92,000 illicit heroin users (540–750 per 100,000 population aged 15 to 64) (<a href="./references#CD003409-bbs2-0108" title="HallW , LynskeyM , DegenhardtL . Heroin use in Australia: its impact on public health and public order. NDARC Monograph No. 42. Sydney, National Drug and Alcohol Research Centre1999. ">Hall 1999</a>). </p> <p>Opioids, mainly heroin, were cited as the primary drug for entering treatment by around 216,000 or 51 % of all those reported entering specialist drug treatment in 29 European countries in 2009. The provision of treatment is central to the reduction of the harms to the individual and the community from opioid dependence. </p> <p>The effect of chronic opioid exposure on opioid receptor levels has not been well‐defined in humans. Tolerance develops through multiple mechanisms, including an acute desensitisation of the opioid receptor (which develops within minutes of opioid use and resolves within hours after use), and a long‐term desensitisation of the opioid receptor (which persists for several days after removal of opioid agonists). Changes also occur in the number of opioid receptors (Williams 2001), and there is compensatory up‐regulation of the cyclic adenosine monophosphate (cAMP) producing enzymes. When the opioid is withdrawn, the cAMP cascade becomes overactive, leading to the “noradrenergic storm” seen clinically as opioid withdrawal, which may create a drive to reinstate substance use. The intensely dysphoric withdrawal syndrome is characterised by watery eyes, runny nose, yawning, sweating, restlessness, irritability, tremor, nausea, vomiting, diarrhoea, increased blood pressure, chills, cramps and muscles aches that can last seven days or even longer. </p> </section> <section id="CD003409-sec-0018"> <h3 class="title" id="CD003409-sec-0018">Description of the intervention</h3> <p>Treatment of opioid dependence is a set of pharmacological and psychosocial interventions aimed at reducing or ceasing opioid use, preventing future harms associated with opioid use, improving quality of life and well‐being of the opioid‐dependent patient. Opioid withdrawal can be managed by controlling the rate of cessation of opioids and by providing medication that relieves symptoms, or by a combination of the two. Methadone at adequate doses prevents or reverses withdrawal symptoms (<a href="./references#CD003409-bbs2-0120" title="WardJ , MattickRP , HallW . Key Issues in Methadone Maintenance Treatment. Sydney: New South Wales University Press, 1992. ">Ward 1992</a>), and thus reduces the need to use illegal heroin (<a href="./references#CD003409-bbs2-0113" title="JaffeJ . Drug addiction and drug abuse. In: AGilman , TRall , ANies , PTaylor editor(s). The Pharmacological Basis of Therapeutics. 8th edition. New York: Pergamon Press, 1990:522‐73. ">Jaffe 1990</a>). Methadone remains effective for approximately 24 hours, requiring a single daily dose rather than the more frequent administration of three to four times daily that occurs with the shorter‐acting heroin (<a href="./references#CD003409-bbs2-0113" title="JaffeJ . Drug addiction and drug abuse. In: AGilman , TRall , ANies , PTaylor editor(s). The Pharmacological Basis of Therapeutics. 8th edition. New York: Pergamon Press, 1990:522‐73. ">Jaffe 1990</a>). </p> </section> <section id="CD003409-sec-0019"> <h3 class="title" id="CD003409-sec-0019">How the intervention might work</h3> <p>Methadone can "block" the euphoric effects of heroin, discouraging illicit use and thereby relieving the user of the need or desire to seek heroin (Dole 1969). This allows the opportunity to engage in normative activities, and "rehabilitation" if necessary. Methadone can cause death in overdosage, like other similar medications such as morphine, and for this reason it is a treatment which is dispensed under medical supervision and relatively strict rules. In summary, methadone is a long‐acting opioid analgesic with well‐understood pharmacological characteristics, which make it suitable for stabilising opioid‐dependent patients in a maintenance treatment approach. Methadone was first used to treat heroin dependence as a tapering agent in US facilities after the second world war and had been introduced in the treatment of opioid dependence for maintenance purposes rather than detoxification until the 1960's. Even though now it is often used for detoxification, sometimes this occurs for economical reasons, sometimes for ideological ones. Despite the risk of relapse being high, detoxification with methadone is common in many countries. The upper limit of duration of the tapered methadone withdrawal period appears to be relatively arbitrary; a period of three to four weeks has been recommended and used in clinical practice (<a href="./references#CD003409-bbs2-0102" title="GossopM , BradleyB , PhillipsGT . Investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21 day inpatient methadone detoxification procedure. Addictive Behaviors1987;12:1‐6. ">Gossop 1987</a>). </p> </section> <section id="CD003409-sec-0020"> <h3 class="title" id="CD003409-sec-0020">Why it is important to do this review</h3> <p>Different pharmacological agents have been used as detoxification agents to ameliorate withdrawal symptoms, however, the rate of completion of detoxification tends to be low, and rates of relapse to opioid use following detoxification are high (<a href="./references#CD003409-bbs2-0103" title="GossopM , GreenL , PhillipsG , BradleyB . Lapse, relapse and survival among opiate addicts after treatment. British Journal of Psychiatry1989;154:348‐53. ">Gossop 1989B</a>; <a href="./references#CD003409-bbs2-0119" title="ValliantGE . What does long‐term follow‐up teach us about relapse and prevention of relapse in addiction?. British Journal of Addiction1988;83:1147‐57. ">Valliant 1988</a>). The present review focuses on detoxification from illicit opiate use through the use of tapered methadone.There are no systematic reviews already published on the effectiveness of methadone at tapered doses on completion of detoxification or relapse rate. </p> <p>The previous version of this review was published in 2005 and an update is required.</p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003409-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003409-sec-0021"></div> <p>To assess the effectiveness of methadone at tapered doses versus placebo or other pharmacological treatments for the management of detoxification on completion and acceptability of the treatment and relapse rate. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003409-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003409-sec-0022"></div> <section id="CD003409-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003409-sec-0024"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and controlled clinical trials (CCTs) on tapered methadone treatment (maximum 30 days) to manage withdrawal from opiates. </p> </section> <section id="CD003409-sec-0025"> <h4 class="title">Types of participants</h4> <p>Opioid users enrolled in short‐term tapered methadone treatment to manage withdrawal from heroin or methadone or buprenorphine, no matter what the characteristic of the setting.Trials including patients with additional diagnoses such as benzodiazepine dependence were also eligible. <br/> <br/> Pregnant women, newborn infants with neonatal dependence and people with iatrogenic dependence (e.g. through treatment of chronic pain) were excluded. The absence in these patient groups of social and psychological factors that underlie opioid dependence makes for a substantially different approach to clinical management. This was the basis for excluding these groups from this review (<a href="./references#CD003409-bbs2-0105" title="GowingL , AliR , WhiteJ . Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD002024.pub3] ">Gowing 2008</a>). </p> </section> <section id="CD003409-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD003409-sec-0027"> <h5 class="title">Experimental Intervention</h5> <p> <ol id="CD003409-list-0001"> <li> <p>Methadone aimed at the detoxification from opiates, maximum length of treatment: 30 days </p> </li> </ol> </p> </section> <section id="CD003409-sec-0028"> <h5 class="title">Control Interventions</h5> <p> <ol id="CD003409-list-0002"> <li> <p>Other opioid agonists (LAAM (levo‐α‐acetyl‐methadol), Buprenorphine, propoxyphene, etc). </p> </li> <li> <p>Adrenergic agonists (clonidine, lofexidine, guanfacine).</p> </li> <li> <p>Opioid antagonists (naltrexone, naloxone).</p> </li> <li> <p>Placebo.</p> </li> </ol> </p> <p>All aimed at the detoxification from opiate.</p> <p>The setting in which withdrawal occurs is a factor that can be expected to influence outcomes. The degree of its effect has been explored by examining rate of completion of withdrawal. </p> </section> </section> <section id="CD003409-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD003409-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003409-list-0003"> <li> <p>Completion of treatment as number of participants completing the detoxification program.</p> </li> <li> <p>Acceptability of the treatment as a) duration and severity of signs and symptoms of withdrawal, including patient self‐rating, b) side effects. </p> </li> <li> <p>Results at follow‐up as (a) number of participants abstinent at follow‐up, (b) naloxone challenge. </p> </li> </ol> </p> </section> <section id="CD003409-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003409-list-0004"> <li> <p>Use of primary substance of abuse as a) number of participants who referred to the use of opioid during the treatment, b) number of participants with urine samples positive for opiate. </p> </li> </ol> </p> <p>Different factors were considered as confounders and taken into account in the analysis wherever possible: setting ( inpatient or outpatient treatment); starting methadone dose/rate and pattern of dose reduction; scheduled duration of treatment; severity of dependence (duration of use, route of administration, frequency of assumption); health status; other treatment offered (psychosocial support); social status; number of previous treatment attempts and previous treatment outcomes. </p> </section> </section> </section> <section id="CD003409-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003409-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies that met the predefined inclusion criteria by searching the following sources from the earliest available date to December 2007. Relevant trials were obtained from the following sources: </p> <p> <ol id="CD003409-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (<i>The Cochrane Library</i> 2012, Issue 4) which include the Cochrane Drugs and Alcohol Group's Register of Trials. </p> </li> <li> <p>PubMed (from 2003 ‐ May 2012).</p> </li> <li> <p>EMBASE (from 2003 ‐ May 2012).</p> </li> <li> <p>CINAHL (from 2003 ‐ December 2011).</p> </li> <li> <p>PsycINFO (January 1985 to December 2004).</p> </li> </ol> </p> <p>To see the search strategies <i>see</i><a href="./appendices#CD003409-sec-0089">Appendix 1</a>; <a href="./appendices#CD003409-sec-0090">Appendix 2</a>; <a href="./appendices#CD003409-sec-0091">Appendix 3</a>; <a href="./appendices#CD003409-sec-0092">Appendix 4</a>. </p> <p>There were no language or publication year restriction.</p> </section> <section id="CD003409-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We also searched:</p> <p> <ol id="CD003409-list-0006"> <li> <p>Reference lists of all relevant papers to identify further studies.</p> </li> <li> <p>Some of the main electronic sources of ongoing trials (meta‐Register of Controlled Trials; Clinical Trials.gov). </p> </li> <li> <p>Conference proceedings likely to contain trials relevant to the review (College on Problems of Drug Dependence ‐CPDD). </p> </li> <li> <p>National focal points for drug  research (e.g., National Institute of Drug Abuse (NIDA), National Drug &amp; Alcohol Research Centre (NDARC). </p> </li> </ol> </p> <p>We contacted authors of included studies and experts in the field in various countries to find out if they know any other published or unpublished controlled trials </p> </section> </section> <section id="CD003409-sec-0035"> <h3 class="title" id="CD003409-sec-0035">Data collection and analysis</h3> <section id="CD003409-sec-0036"> <h4 class="title">Selection of studies</h4> <p>One review author (Amato) inspected the search hits by reading the titles and the abstracts. We obtained each potentially relevant study located in the search in full text and two review authors (Amato, Minozzi) independently assessed for inclusion. Doubts were resolved by discussion between the review authors. </p> </section> <section id="CD003409-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (Amato, Minozzi) independently extracted data from published sources using a data extraction form. Where differences in data extracted occurred this was resolved through discussion. Study quality was assessed by Silvia Minozzi according to the criteria indicated in <i>Cochrane Handbook for Systematic Reviews of Interventions</i> 4.2. (<a href="./references#CD003409-bbs2-0110" title="HigginsJPT , Green S (editors). The Cochrane Collaboration, 2008 . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane‐handbook.org.. ">Higgins 2008</a>) </p> </section> <section id="CD003409-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias assessment  for RCTs and CCTs in this review were performed using the five criteria recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003409-bbs2-0110" title="HigginsJPT , Green S (editors). The Cochrane Collaboration, 2008 . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane‐handbook.org.. ">Higgins 2008</a>). The recommended approach for assessing risk of bias in studies included in Cochrane reviews is a two‐part tool, addressing five specific domains (namely sequence generation, allocation concealment, blinding, incomplete outcome data, and other issues). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre‐specified question about the adequacy of the study in relation to the entry, such that a judgement of "Yes" indicates low risk of bias, "No" indicates high risk of bias, and "Unclear" indicates unclear or unknown risk of bias. To make these judgments we used the criteria indicated by the handbook adapted to the addiction field. </p> <p>Blinding of participants, personnel and outcome assessor (avoidance of performance bias and detection bias) were considered separately for objective outcomes (e.g. drop‐out, use of substance of abuse measured by urinalysis, participants relapsed at the end of follow‐up, participants engaged in further treatments) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, patient self‐reported use of substance, side effects, social functioning as integration at school or at work, family relationship). </p> <p>Incomplete outcome data (avoidance of attrition bias) were considered for all outcomes except for the drop‐out from the treatment, which is very often the primary outcome measure in trials on addiction. It was assessed separately for results at the end of the study period and for results at follow‐up. </p> <section id="CD003409-sec-0039"> <h5 class="title">Grading of evidence</h5> <p>The quality of evidence was assessed according to a systematic and explicit method (<a href="./references#CD003409-bbs2-0106" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). In order to indicate the extent to which one can be confident that an estimate of effect is correct, judgments about the quality of evidence are made for each comparison and outcome. These judgments consider study design (RCT, quasi‐RCT or observational study), study quality (detailed study design and execution), consistency of results (similarity of estimates of effect across studies), precision of estimates, and directness (the extent to which people, interventions and outcome measures are similar to those of interest). The following definitions in grading the quality of evidence for each outcome are used: High: further research is very unlikely to change our confidence in the estimate of effect. Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low: further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Very low: any estimate of effect is very uncertain. </p> </section> </section> <section id="CD003409-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <p>We compared the treatment and control groups for outcomes at post‐test and at different follow‐up times. Post‐intervention data were collected immediately after the intervention ended. For continuous data it was not possible to pool data due to the heterogeneity of reporting in the included studies. </p> </section> <section id="CD003409-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>Statisticians often use the terms ‘missing at random’, and ‘not missing at random’ to represent different scenarios. Data are said to be ‘missing at random’ if the fact that they are missing is unrelated to actual values of the missing data. Data are said to be ‘not missing at random’ if the fact that they are missing is related to the actual missing data. In cases where we assumed that data were missing at random, we analysed only the available data. If we assumed that the data were not missing at random, we planned to impute the missing data with replacement values, and to treat these as if they were observed. We planned to do this in different ways and compare the results (e.g. last observation carried forward, imputing an assumed outcome such as assuming all were poor outcomes, imputing the mean, imputing based on predicted values from a regression analysis). For the included studies in this review we did not impute data. </p> </section> <section id="CD003409-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistically significant heterogeneity among primary outcome studies was assessed with Chi<sup>2</sup> (Q) test and I<sup>2</sup> (Higgins 2003). A significant Q ( P &lt;.05) and I‐squared of at least 50% was considered as statistical heterogeneity. </p> </section> <section id="CD003409-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots for information about possible publication bias. But asymmetric funnel plots are not necessarily caused by publication bias (and publication bias does not necessarily cause asymmetry in a funnel plot). Whenever asymmetry was present, likely reasons were explored. </p> </section> <section id="CD003409-sec-0044"> <h4 class="title">Data synthesis</h4> <p>Dichotomous outcomes (completion of treatment, number of participants with negative urinalysis) were analysed calculating the risk ratio (RR) for each trial with the uncertainty in each result being expressed by their confidence intervals (CIs). The RRs from the individual trials were combined through meta‐analysis where possible (comparability of intervention between trials) using a random‐effects model. The completion of the treatment was reported as the number of patients who completed the detoxification program. The use of primary substance was reported as the number of participants with consecutive negative urinalysis. The results at follow‐up were reported as the number of participants abstinent at the follow‐up interview (range of follow‐up period: one to six months). We used the Chi<sup>2</sup> test to determine the heterogeneity of the results. A P value of the Chi<sup>2</sup> test less than 0.005 indicated a significant heterogeneity. </p> </section> <section id="CD003409-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>The following sensitivity analyses were planned <i>a priori:</i> Generation of allocation sequence, concealment of allocation, blinding of patients and providers, blinding of assessors, incomplete outcome data addressed, selective reporting, and other bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003409-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003409-sec-0046"></div> <section id="CD003409-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD003409-sec-0048"> <h4 class="title">Results of the search</h4> <p>The literature searching process resulted in the identification of 8545 reports (6860 after duplicates removed), 6754 were excluded on the basis of title and abstract, 106 were retrieved in full text; 74 have been excluded and 23 (32 references) included, 17 studies included in quantitative synthesis (meta‐analysis). <i>See</i><a href="#CD003409-fig-0001">Figure 1</a> </p> <div class="figure" id="CD003409-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart of studies" data-id="CD003409-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart of studies</p> </div> </div> </div> </section> <section id="CD003409-sec-0049"> <h4 class="title">Included studies</h4> <p>Twenty‐three studies (32 reports) meet the inclusion criteria for this review <i>see</i><a href="./references#CD003409-sec-0101" title="">Characteristics of included studies</a>. </p> <p><b><i>Duration of trials:</i> </b> range three to 30 days. <br/> <b><i>Treatment regimens and setting:</i> </b> The countries in which the 23 studies were conducted are: USA (six studies), United Kingdom (five studies), Spain (four studies), China, Irane and Germany (two studies each), Austria and Italy (one study each). Eighteen trials were conducted with inpatients, five with outpatients. Information on methadone doses were available for 19 of the 23 included studies. The mean starting dose of methadone was 29 mg/day (range 15 to 60). The other four studies reported that the starting doses of methadone were variable, tailored on individual body weight or heroin consumption in the previous month. </p> <p><b><i>Participants:</i> </b> 2467 opiate addicts. Age range was 18 to 70 years; one study (<a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>) did not report age characteristics only that participants were required to be under 55 years old. </p> <p><b><i>Comparisons:</i> </b> <br/> In the 23 studies included in the review, tapered methadone was compared with the following. </p> <p> <ol id="CD003409-list-0007"> <li> <p>Tapered methadone versus any other treatments: 23 studies, 2467 participants.</p> </li> <li> <p>Tapered methadone versus adrenergic agonists: 11 studies, (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a>; <a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a>; <a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a>; <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>), 952 participants. </p> </li> <li> <p>Tapered methadone versus other opioid agonists: eight studies, (<a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>;<a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>; <a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a>), 869 participants. </p> </li> <li> <p>Tapered methadone versus anxiolytic: two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>), 47 participants. </p> </li> <li> <p>Tapered methadone versus placebo: two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>), 38 participants. </p> </li> <li> <p>Tapered methadone versus paiduyangsheng: one study (<a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a>), 580 participants. </p> </li> </ol> </p> <p>One study (<a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>) has three arms, comparing methadone (arm 1) with buprenorphine (arm 2) and with clonidine (arm 3). For this study the participants in the methadone arm (21 people) are considered both in the comparison with adrenergic agonists and in the comparison with other opioid agonists. Another study (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>) has four arms comparing methadone (arm 1) with placebo (arm 2), buspirone 30 mg (arm 3), buspirone 45 mg (arm 4). For this study the participants in the methadone arm (eight people) are considered in all the comparisons. </p> <p>Two studies (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>) had three arms comparing methadone with different dosages of adrenergic agonist. For these studies we summarised the results of the two different dosages of adrenergic agonists. One study (<a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>) compared methadone with two different adrenergic agonists and we summarised the results of the two different adrenergic agonists. </p> <p><b><i>Outcomes:</i> </b> <br/> Outcomes were either dichotomous or continuous, as reported by authors. The following principal outcomes were considered by the authors. </p> <p> <ol id="CD003409-list-0008"> <li> <p>Completion of treatment as number of participants completing the detoxification program (16/23 studies). </p> </li> <li> <p>Withdrawal scores (21/23 studies).</p> </li> <li> <p>Side effects (16/23 studies).</p> </li> <li> <p>Use of primary substance measured as number of opiate positive urine samples (3/23 studies). </p> </li> <li> <p>Results at follow‐up as (a) number of participants abstinent at follow‐up (4/23 studies) and (b) naloxone challenge (2/23 studies). </p> </li> </ol> </p> <p><b><i>Scales</i> </b> <br/> The 23 studies that used withdrawal scales to assess withdrawal symptoms used 22 different scales (see <a href="#CD003409-tbl-0002">Table 1</a> ), of which 15 were published. Furthermore, four studies considered craving using four different methods to assess it: Craving questionnaire (<a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a>), Craving Scale (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>), Severity of Dependence Scale (SDS) (<a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>) and Addiction Severity Index ( <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>). Five studies use questionnaires to assess psychological and behavioural characteristics: State Trait Anxiety Inventory (<a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>), Beck Depression Inventory (<a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>, <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>), Eysenck Personality Questionnaire (<a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>), Hamilton Anxiety Rating Scale (<a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a>) Profile of Mood State (<a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>), Hospital Anxiety Depression (<a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>). One study used an Intelligence Quotient test: Wechsler Adult Intelligence Scale (<a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>). </p> <div class="table" id="CD003409-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawal scales</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name of Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Published</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n° items</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n° scores</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>present/absent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptom Checklist (<a href="./references#CD003409-bbs2-0116" title="PowellJ , GrayJA , BradleyBP , KasvikisY , StrangJ , BarrattL , et al. The effects of cue exposure to drug‐related cues in detoxified opiate addicts: a theoretical review and some new data. Addictive Behavior1990;15:339‐54. ">Powell 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective Measures Questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0112" title="HimmelsbachCK . Clinical studies of drug addiction: physical dependence, withdrawal and recovery. Archives of Internal Medicine1942;69:766‐72. ">Himmelsbach 1942</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>List of Withdrawal Symptoms (<a href="./references#CD003409-bbs2-0101" title="GerraG , MarcatoA , CavaccariR , FontanesiB , DelsignoreR , FertonaniG , et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse treatment1995;12:35‐41. ">Gerra 1995</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal Problem Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self Rated Withdrawal Scale (<a href="./references#CD003409-bbs2-0107" title="HaertzenCA , MeketonMJ . Opiate withdrawal measured by the Addiction Research Center Inventory (ARCI). Diseases of the Nervous sSystem1968;29:450‐5. ">Haertzen 1968</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observer rating scale (<a href="./references#CD003409-bbs2-0114" title="KolbL , HimmelsbachCK . Clinical studies of drug addiction III. American journal of Psichiatry1938;94:759‐99. ">Kolb 1938</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short OpioidWithdrawal Scale [German version] (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily Abstinence Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>present/absent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Signs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Checklist (<a href="./references#CD003409-bbs2-0117" title="SchubertH , FleischackerW , MeiseV , TheoharC . Preliminary results of guanfacine treatment of acute opiate withdrawal. American Journal of Psichiatry1984;141:1271‐3. ">Schubert 1984</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Checklist (<a href="./references#CD003409-bbs2-0117" title="SchubertH , FleischackerW , MeiseV , TheoharC . Preliminary results of guanfacine treatment of acute opiate withdrawal. American Journal of Psichiatry1984;141:1271‐3. ">Schubert 1984</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Syndrome (<a href="./references#CD003409-bbs2-0098" title="BradleyBP , GossopM , PhillipsGT , LegardaJJ . The development of an Opiate Withdrawal Scale (OWS). British Journal of Addiction1987;82:1139‐42. ">Bradley 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Witdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detoxification Symptom Scale (Fulwiler 1979)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0121" title="WessonDR , LingW . The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs2003;35(2):253‐9. ">Wesson 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Witdrawal Syndrome Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observer Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0115" title="PeacheyJ , LeiH . Assessment of opioid dependence with naloxone. British Journal of Addictions1988;83:193‐201. ">Peachey 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003409-sec-0050"> <h4 class="title">Excluded studies</h4> <p>Seventhy‐four studies did not meet the criteria for inclusion in this review. The grounds for exclusion were: type of intervention: 39 studies; study design: 29 studies; study design and type of intervention: three studies; type of participants:one study; type of intervention and type of participants: one study, type of intervention and type of outcomes: one study; <i>see</i><a href="./references#CD003409-sec-0102" title="">Characteristics of excluded studies</a> </p> </section> </section> <section id="CD003409-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall the quality of the included studies was good, see <a href="#CD003409-fig-0002">Figure 2</a>; <a href="#CD003409-fig-0003">Figure 3</a>. Below the results of the single risk of bias are considered. </p> <div class="figure" id="CD003409-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003409-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003409-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003409-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD003409-sec-0052"> <h4 class="title">Allocation</h4> <p>Random Sequence Generation: three studies (<a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>) were judged at low risk of selection bias because the investigators described a random component in the sequence generation process. The other 20 studies were judged as having an unclear risk of bias because there was insufficient information about the sequence generation process to permit judgement. </p> <p>Allocation concealment: seven studies (<a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>) were judged at low risk of selection bias because investigators enrolling participants could not foresee assignment and the method of allocation concealment was described. The other 16 studies were judged at unclear risk because they did not describe the method of concealment or did not describe it in sufficient detail to allow a definite judgement. </p> </section> <section id="CD003409-sec-0053"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel: 18 studies (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a>; <a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a>; <a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>; <a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>; <a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a>) were judged to be at low risk of performance bias because participants and  providers were blinded and it was unlikely that the blinding could have been broken. One study (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>) was judged at high risk of bias because it was not blinded and the remaining four studies (<a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>; <a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a>) were judged at unclear risk because it was not clear if a blinding condition had been undertaken. </p> <p>Blinding of outcomes assessor: 12 studies (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>; <a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a>) were judged at low risk of detection bias because it was specified that the outcome assessor was blinded. One study (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>) was judged at high risk of bias because there was no blinding of outcome assessment. The remaining 10 studies were judged as having an unclear risk of bias because it was not clear if the outcome assessor was blind to treatment allocation. </p> </section> <section id="CD003409-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Fiftheen studies (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a>; <a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>; <a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>; <a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>) were judged at low risk of attrition bias because all randomised patients were reported/analysed in the group to which they were allocated by randomisation, irrespective of non‐compliance and co‐interventions (intention‐to‐treat) or had no missing outcome data. Two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a>) were judged at high risk and the remaining six studies were judged at unclear risk. </p> <p>Nevertheless, many outcomes could not be summarised because they were presented in graphical form or only provided statistical tests and P values. For most of the continuous variables standard deviation was not provided. Furthermore, the authors used different scales to compare the same or very similar outcomes and this makes it impossible to compare them. <br/> <br/> In particular for the outcomes which we considered as possible confounders such as setting, starting methadone dose, severity of dependence, health status etc. and for others for example, patients' motivation at enrolment, it was not possible to perform statistical analysis because many authors did not report the relevant data and, were these were available, the data were heterogeneously reported. </p> </section> </section> <section id="CD003409-sec-0055"> <h3 class="title" id="CD003409-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD003409-tbl-0001"><b>Summary of findings for the main comparison</b> Tapered methadone versus any other treatment for the management of opioid withdrawal</a> </p> <p>The results were summarised, with comparison of quantitative data where possible, first for methadone versus any other treatment and then comparing separately methadone versus single different treatments. </p> <section id="CD003409-sec-0056"> <h4 class="title">1. Tapered methadone versus any other pharmacological treatment</h4> <section id="CD003409-sec-0057"> <h5 class="title">1.1 Completion of treatment</h5> <p>Sixteen studies (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>), 1381 participants risk ratio (RR) 1.08 (95% confidence interval (CI) 0.97 to 1.21); the difference was not statistically significant, <i>see</i><a href="#CD003409-fig-0004">Figure 4</a> or <a href="./references#CD003409-fig-0006" title="">Analysis 1.1</a>, </p> <div class="figure" id="CD003409-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.1 Completion of treatment." data-id="CD003409-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.1 Completion of treatment. </p> </div> </div> </div> </section> <section id="CD003409-sec-0058"> <h5 class="title">1.2 Results at follow‐up as number of participants abstinent at follow‐up</h5> <p>Three studies (<a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>), 386 participants (RR 0.98; 95% CI 0.70 to 1.37); the difference was not statistically significant, <i>see</i><a href="#CD003409-fig-0005">Figure 5</a> or <a href="./references#CD003409-fig-0007" title="">Analysis 1.2</a> </p> <div class="figure" id="CD003409-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.2 Number of participants abstinent at follow‐up." data-id="CD003409-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.2 Number of participants abstinent at follow‐up. </p> </div> </div> </div> <section id="CD003409-sec-0059"> <h6 class="title">Results at follow‐up as naloxone challenge</h6> <p>Two studies reported data on this outcome, but only <a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a> reported the rate of participants who accepted and continued naltrexone treatment: in the methadone group 9/34, in clonidine five days 17/32; RR 0.50 (95% CI 0.26 to 0.95), the difference was statistically significant in favour of clonidine. <br/> <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a> referred data for all the participants without distinction between the groups: of the eight participants who were opiate free at completion of the study, six began treatment with naltrexone. </p> </section> <section id="CD003409-sec-0060"> <h6 class="title">Duration and severity of signs and symptoms of withdrawal</h6> <p>The diversity of approaches used for rating withdrawal severity, prevented a direct comparison of scores across studies. Different rating instruments were utilised and for many of them, the authors did not indicate the scores considered to represent boundaries of mild, moderate and severe to allow comparison of results between studies. The 21/23 studies that considered this outcome varied in how severity was rated and in the form in which results were reported. In some studies withdrawal was assessed by observers only, in others it was reported by participants and in others by both. In one study (<a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>), withdrawal was not systematically assessed and it was unclear how the assessment was undertaken. The diversity of approaches used for rating withdrawal severity prevented a direct comparison of scores across studies, consequently, we have not been able to make a quantitative analysis of the intensity of withdrawal. We tried to summarise the results in <a href="#CD003409-tbl-0003">Table 2</a>; <a href="#CD003409-tbl-0004">Table 3</a>; <a href="#CD003409-tbl-0005">Table 4</a>; <a href="#CD003409-tbl-0006">Table 5</a>; <a href="#CD003409-tbl-0007">Table 6</a>. </p> <div class="table" id="CD003409-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus adrenergic agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean scores higher for (1) on days 13‐21 and for (2) days 2‐12. Peak score on (1) day 13 and (2) day 10. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2) 2 both female, experienced dizziness due to postural hypotension.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscular aching, flatulence and drowsiness more common in (1). Sleep disturbance &amp; weeping in (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of (2) had transferred loss of consciousness. (2) 4 (1) 1 experienced orthostatic hypotension. A graph shows a steady decline and similar magnitude in both groups regarding adverse effects, from days 1 to 6. After day 6, the scores for (1) increased, while in (2) continued to decline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimum withdrawal scores, mean (1) 25 (2) 33; maximum (1) 69 (2) 53. Time points minimum (1) day 1 (2) day 7, maximum (1) day 10 (2) day 2/3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In (2) mean scores slightly lower but not significantly lower than (3). During the last 4 days of treatment and after the first 4 days after methadone discontinuation; (1) mean scores significantly higher (2) than (3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily blood pressure only for (2) &amp; (3): no significant differences at any point. (2) 3 (3) 2 experienced side effects necessitate dose reduction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lowest daily score: mean (1) 49.4 (2) 50.0 ; Highest daily score: mean (1) 67.6 (2) 69.3; Total mean (1) 572.1 (2) 596.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sitting blood pressure in (2) 4/32 lowest 61 mmHg, in (1) 3/36 lowest 80 mmHg, NS Depressive symptoms in 2 patients, one in each treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>On day 1 no significant differences in the two groups, between days 2 and 4 higher in (2), between days 8 and 12 lower in (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The scores higher in (2) compared to (1) from days 1 to 7, the greatest difference occurred on day 2 of treatment when the mean side effects scores was (1) 1.9 and (2) 8.2. The score subsequently declined in both groups. Comparison of each undesirable side effect suggests that general tiredness, weakness in walking, dizziness in standing position, dry mouth and lethargy are most common occurrences in (2), while in (1) only a small numbers of patients experienced general tiredness, weakness in walking, dry mouth and lethargy . In (2) 89 experienced dizziness on standing, mostly in the second and third days of treatment. Anxiety scores were significantly lower in (2) by day 11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean withdrawal scores at baseline and weeks 1‐2‐3‐4: at baseline no differences, during the first 2 weeks (1) 7.6, (2) 19.0, during the second two weeks (1) 13,0 (2) 12,0 ; Rates of withdrawal symptoms: (2) higher than (1); Comparison of withdrawal characteristics of success and failure in the groups were not statistically different. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of side effects, rated by physicians and nurses: (1) 11,5 (2) 16,8. Characteristics of side effects: for the majority of symptoms there were no differences among the two groups. Number using sleep medications: (1) 70% (2) 63%; Scores of Beck Depression Inventory between successfully drug‐free or not patients in the 2 groups were respectively: 54% and 17%. For the same groups, the percentage above the median for each ASI area were as follows: for medical area 62% and 46%, for employment 50% and 22%, for legal 35% and 22% , for family/social 31% and 28%, for psychological 31% and 28%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (graph): Significant differences between (1) and (2) on days 2, 3, 4 and 5, higher in (1); between (1) and (3) on days 2, 3, 4 and 11, higher in (3); no significant differences between (2) and (3); the maximum mean was (1) 4.9, (2) 8.1, (3) 7.6 all on day 2. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotensive effect more intense in (2); changes in heart rate more pronounced in (2) than in (3); (1) and (3) most frequent side effects: asthenia, dry mouth, flushing, mental clouding, thirst. . Differences in personality tests and patient's mood: NS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (graph): from day 9 higher in (2) and (3) for three days and in (1) after day 11, statistically significant between (1) and (3) on days 10,11 higher in (3); and between (1) and (2) on days 11,15, higher in (1); on day 20 higher in (3) compared with (1) and (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differences in blood pressure and heart rate: for blood pressure, in (3) after day 13 grater decrease than in (1) and (2); for heart rate, in (3) bradycardia from day 9 with lowest rate on day 11, (62 beats per min); statistical significant difference between (3) compared with (1) and (2) in days 9, 10,11, 12,16, 17, 18, 19. Differences in personality tests and patient's mood: NS. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean withdrawal scores at baseline, after the first dose of medication and during the treatment no significant differences in the magnitude of the decrease in withdrawal between the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 patients in (3) had to withdraw from the study because of decreased systolic blood pressure (&lt; 90 mmHg) and bradycardia (HR &lt; 50 BPM) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major symptomatic complaints, specifically lethargy, restlessness and insomnia were identical for both groups. The main items contributing to scores in both groups were sleep problems, anxiety/nervousness, irritability, lack of energy, aches/pains and feeling cold. (2) reported symptoms during the 1° week of the study whereas (1) in the last week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy and sluggishness most consistent complaints in (2).</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003409-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus other opioid agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Changes in signs and symptoms of opioid withdrawal [12‐item German version of the Short Opioid Withdrawal Scale] assessed on days 0, 3, 7, 10, 14, 18 and 22 by patient self‐rating. </p> <p>At study entry signs and symptoms of withdrawal were mild but deteriorated steadily over time (day 0 versus day 22, P &lt; 0.001). The only difference between the groups was found on day 18 (P = 0.022). All symptoms showed a homogeneous pattern of changes. (1) day 0 8.15 6.48 (7.00), day 22 16.00 7.81(15.00) P &lt; 0.001; (2) day 0: 8.07 6.09 (7.00) day 22:18.32 8.98 (18.00) P &lt; 0.001 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events was low; 16 (16%) patients in the SRM group and 13 (13%) patients in the methadone group experienced at least one adverse event (c2 test, P = 0.586). Thirty of 45 (67%) of all adverse events were rated as being unrelated, nine (20%) as possibly related (SRM: six patients; methadone: three patients) and one (2%) (methadone group) as probably related to the study drug. The majority of adverse events (23 of 45) were gastrointestinal system disorders, such as <br/> nausea (three), vomiting (10), dentalgia (five), followed by psychiatric disorders (seven of 45, e.g. dysphoria, agitation, depression, panic attacks). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOWS score (days 0‐2): no differences; weeks 1‐2 (2) fewer symptoms than (1); no differences in self‐rating scales </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean symptom discomfort index initially declined then increased with drug taper. Initial, stabilisation and final ratings by graph: (1)18, 10, 15 (2) 16, 7, 16. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 overdose incident, possibly due to combination with alcohol.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results in favour of buprenorphine only in the first day of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (1) 6.6 (2) 9.6. Difference significant on days 8, 12, 15, 16, 17. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one statistically significant difference. (1)6 [16.7%], (2)17 [47%] reported euphoria. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant and observer rating scales: after first‐dose effect, further improvements were minimal, and overall mean scores during treatment were not significantly lower than scores after one treatment dose. The overall mean time averaged decreases ranged from‐5.1 to ‐6.0 for OOWS and ‐3.3 to ‐4.7 for SOWS. No significant differences in the magnitude of the decrease in the withdrawal between the treatment groups. At no time during treatment did withdrawal scores exceed baseline scores for any individual. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No major changes in blood pressure or heart rate during the observation time interval of the study. There was a trend (P = 0.06) toward myosis in the buprenorphine and methadone groups, consistent with a pharmacologic effect of treatment. Systolic blood pressure decreased significantly in the buprenorphine group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statistical analysis revealed that significant decreases (P ≤ .04) were found in the OOWS scores in both treatment methods up to day 14; no statistically significant difference was found between OOWS scores of the treatment methods at different intervals (P ≥ .1), except for day 6 of the study (P = .03) where results were in favour of tramadol. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant differences were observed in side effects scores for dizziness, somnolence, ataxia, constipation, nausea, seizures, and respiratory depression between two treatment methods, except for perspiration and pain, which were significantly higher in tramadol (P = .02) and methadone (P = 0.01) treatment methods, respectively </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OOWS: Objective Opioid Withdrawal Scale; SOWS: Short Opioid Withdrawal Scale</p> </div> </div> <div class="table" id="CD003409-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus anxiolytics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective and Objective withdrawal scale: no significant differences between methadone and buspirone doses </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher scores in the chlordiazepoxide group only on day 3; at the end of the study, the scores were higher in the methadone group but not statistically significant. Analysis of individual items in the OWS (Opiate Withdrawal Scale) failed to implicate any particular item as being responsible for the difference between the two groups. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In methadone group relative bradycardia is more present in the first days of treatment and the difference with respect to the chlordiazepoxide group became statistically significant on days 4 and 7. As methadone was gradually withdrawn, the mean heart rate returned to a level comparable to the beginning period. Mean pupil size was less in methadone group during the treatment period and the difference was statistically significant on day 5, similarly mean temperature was lower in this group on day 3. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003409-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective and Objective scales: symptoms in placebo group were significantly more pronounced </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores in the placebo groups, with the most severe symptoms on day 1 to 15. 8/11 placebo‐treated patients needed to be switched from placebo to methadone because the OWC (Opiate Withdrawal Checklist) daily score was &gt; 15. With respect to features of the withdrawal syndrome in placebo patients, two stages were observed: anxiety, chills, gooseflesh, myalgia and weakness were the most common on day 1 to 5 and sleep disturbance persisted on day 6 to 13. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003409-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus paiduyangsheng</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003409-sec-0061"> <h6 class="title">Side effects</h6> <p>Adverse effects were reported in 12/23 studies and assessed in different ways. This variability prevented quantitative analysis of this outcome. Data are reported in <a href="#CD003409-tbl-0003">Table 2</a>; <a href="#CD003409-tbl-0004">Table 3</a>; <a href="#CD003409-tbl-0005">Table 4</a>; <a href="#CD003409-tbl-0006">Table 5</a>. </p> </section> <section id="CD003409-sec-0062"> <h6 class="title">Use of primary substance as Number of participants with opiate positive urinalysis during the treatment </h6> <p>Only 3/22 studies (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>) reported data on the use of opiate during the treatment but their modalities of reporting results of urinalysis was heterogeneous, making meta‐analysis difficult to be carried out. Results as reported in the articles are hardly informative, and data presented as number of positive tests over number of tests cannot be properly analysed through meta‐analysis. In fact using tests instead of the participants as the unit of analysis violates the hypothesis of independence among observations, and makes the results of tests done in each patient not independent. </p> </section> </section> </section> <section id="CD003409-sec-0063"> <h4 class="title">2. Tapered methadone versus adrenergic agonists</h4> <section id="CD003409-sec-0064"> <h5 class="title">2.1 Completion of treatment</h5> <p>Seven studies (<a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a>; <a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a>; <a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>; <a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a>), 577 participants RR 1.10 (95% CI 0.91to 1.32); the difference was not statistically significant, <i>see</i><a href="./references#CD003409-fig-0008" title="">Analysis 2.1</a>, </p> <section id="CD003409-sec-0065"> <h6 class="title">Use of primary substance as number of participants with opiate positive urinalysis during the treatment </h6> <p>One study (<a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a>), reported results of urine screening that showed a significantly higher rate of positive samples for morphine catabolites in the methadone and clonidine five‐days groups in respect of clonidine three days plus oxazepam, baclofen and ketoprofen group. No significant difference was found between the first two groups. In the methadone group, the positive urine rate increased significantly from day one to day 10. </p> </section> <section id="CD003409-sec-0066"> <h6 class="title">Results at follow‐up as number of participants abstinent at follow‐up</h6> <p>One study (<a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a>), reported the number of participants abstinent at follow‐up at one month: 6/18 in methadone group and 4/15 in the clonidine group; at three months 5/19 in methadone and 4/15 in clonidine groups; at six months 7/18 in methadone and 3/13 in clonidine group. The differences were never statistically significant. </p> </section> </section> </section> <section id="CD003409-sec-0067"> <h4 class="title">3. Tapered methadone versus any other opioid agonist</h4> <section id="CD003409-sec-0068"> <h5 class="title">3.1 Completion of treatment</h5> <p>Seven studies (<a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>; <a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>), 695 participants RR 1.10 (95% CI 0.89 to 1.37); the difference was not statistically significant, <i>see</i><a href="./references#CD003409-fig-0009" title="">Analysis 3.1</a>. </p> <section id="CD003409-sec-0069"> <h6 class="title">Use of primary substance as number of participants with opiate positive urinalysis during the treatment </h6> <p>Two studies (<a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>; <a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>) considered this outcome. </p> <p> <ul id="CD003409-list-0009"> <li> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>, (tapered methadone versus LAAM) reported that the proportion of participants using opiates never dropped below 50% for any group at any time. Exact figures were not reported, data were presented only in a graph. The groups did not differ in the percentage of urine samples that contained opiates overall. </p> </li> <li> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>, (tapered methadone versus propoxyphene) reported the number of participants who had opiate‐negative urine on at least one occasion: 27/36 (75%) in methadone group and 19/36 (53%) in propoxyphene group; the difference is not statistically significant. </p> </li> </ul> </p> </section> <section id="CD003409-sec-0070"> <h6 class="title">Results at follow‐up as number of participants abstinent at follow‐up</h6> <p>Three studies reported this outcome.</p> <p> <ul id="CD003409-list-0010"> <li> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>: (tapered methadone versus LAAM), the data were reported for all the participants without distinction between the groups of treatment 57/61 participants gave consent to be interviewed: 24/49 reported that they abstained from heroin &gt; one day after detoxification, at three months 2/49 abstinent, 25/49 sought further treatment and 9/49 enrolled in methadone maintenance treatment. </p> </li> <li> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>: (tapered methadone versus propoxyphene) reported that at one month follow‐up the number of abstinent were 15/32 in the methadone group and 13/32 in propoxyphene group; the difference is not statistically significant. </p> </li> <li> <p><a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>: (tapered methadone versus tapered buprenorphine) reported that at eight days post detoxification, there was no statistically significant difference in the odds of achieving abstinence between the methadone and buprenorphine arms (odds ratio (OR) = 1.69; 95% CI = 0.81 to 3.51; P = 0.163). Similarly, there was no statistically significant difference at one month (OR = 0.38; 95% CI = 0.13 to 1.10; P = 0.074) or three months (OR = 0.38; 95% CI = 0.13 to 1.10; P = 0.074), and insufficient data at the six‐month time point to undertake statistical analysis. </p> </li> </ul> </p> </section> </section> <section id="CD003409-sec-0071"> <h5 class="title">3.2 Tapered methadone versus buprenorphine</h5> <section id="CD003409-sec-0072"> <h6 class="title">Completion of treatment</h6> <p>Four studies (<a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a>; <a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a>; <a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a>; <a href="./references#CD003409-bbs2-0021" title="SheardL , WrightNM , AdamsCE , BoundN , RushforthB , HartR , et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS)Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials2009;10:53. WrightNM , SheardL , AdamsCE , RushforthBJ , HarrisonW , BoundN , et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. The British Journal of General Practice: the journal of the Royal College of General Practitioners2011;61(593):772‐80. ">Wright 2011</a>) 390 participants RR 0.97 (CI 95% 0.69 to 1.37), the difference was not statistically significant, <i>see</i><a href="./references#CD003409-fig-0010" title="">Analysis 3.2</a>. </p> </section> </section> <section id="CD003409-sec-0073"> <h5 class="title">3.3 Furthermore, single studies considered completion of treatment for the following comparisons </h5> <p> <ul id="CD003409-list-0011"> <li> <p>versus LAAM (<a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a>), 5/15 patients in the methadone group and 4/13 in the LAAM group completed the treatment; RR 1.08 (CI 95% 0.37 to 3.21), the difference was not statistically significant but showed a trend in favour of LAAM; </p> </li> <li> <p>versus propoxyphene (<a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a>), 25/36 in the methadone group and 15/36 in the propoxyphene group completed the treatment; RR 1.67 (CI 95% 1.07 to 2.60), the difference was statistically significant in favour of methadone group; </p> </li> <li> <p>versus slow release morphine (<a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a>), 49/100 in the methadone group and 50/102 in the slow release morphine group completed the treatment, RR 1.00 (CI 95% 0.75 to 1.32), the difference was not statistically significant. </p> </li> </ul> </p> </section> </section> <section id="CD003409-sec-0074"> <h4 class="title">4. Tapered methadone versus anxiolytic</h4> <section id="CD003409-sec-0075"> <h5 class="title">4.1 Completion of treatment</h5> <p>Two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>), 47 participants RR 0.63 (CI 95% 0.18 to 2.24), the difference was not statistically significant and it should be considered that in one of the two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>) all the participants in both groups completed the treatment, <i>see</i><a href="./references#CD003409-fig-0011" title="">Analysis 4.1</a>. </p> </section> </section> <section id="CD003409-sec-0076"> <h4 class="title">5.Tapered methadone versus placebo</h4> <section id="CD003409-sec-0077"> <h5 class="title">5.1 Completion of treatment</h5> <p>Two studies (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>; <a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a>), 38 participants RR 1.95 (CI 95% 1.21 to 3.13), in favour of methadone, see <a href="./references#CD003409-fig-0012" title="">Analysis 5.1</a>, </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003409-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003409-sec-0078"></div> <section id="CD003409-sec-0079"> <h3 class="title" id="CD003409-sec-0079">Summary of main results</h3> <p>Comparing methadone with other pharmacological treatments aimed at detoxification, studies showed no substantial clinical difference between the treatments in terms of completion of treatment, 16 studies 1381 participants, risk ratio (RR) 1.08 (95% confidence interval (CI) 0.97 to 1.21), number of participants abstinent at follow‐up, three studies, 386 participants (RR 0.98; 95% CI 0.70 to 1.37) and degree of discomfort for withdrawal symptoms and adverse events. </p> <p>Comparing methadone with adrenergic agonists, studies showed no substantial clinical difference between the treatments in terms of completion of treatment, seven studies, 577 participants RR 1.10 (95% CI 0.91 to 1.32). with regard to the withdrawal symptoms and side effects, early withdrawal symptoms were less adequately controlled with lofexidine than methadone; in the methadone groups the symptoms were experienced only in the latter stages of treatment when the dosage of the substance was drastically reduced. Only in two single studies (<a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a>; <a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a>) was methadone more effective than adrenergic agonists in decreasing withdrawal signs and symptoms and causing fewer side effects. </p> <p>Comparing methadone with other opioid agonists, the results did not show differences between the groups with regard to completion of treatment, seven studies, 695 participants RR 1.10 (95% CI 0.89 to 1.37) and the acceptability of the treatment. Comparing methadone with buprenorphine, no differences were found for completion of treatment, four studies, 390 participants RR 0.97 (CI 95% 0.69 to 1.37). </p> <p>Comparing methadone with the anxiolytic buspirone (<a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a>) and chlordiazepoxide (<a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a>) results did not show differences between the groups in terms of completion of treatment, two studies, 47 participants RR 0.91 (95% CI 0.47 to 1.77). </p> <p>Comparing tapered methadone with placebo, studies showed, as expected, results in favour of methadone for completion of treatment, two studies, 38 participants RR1.95 (95% CI 1.21 to 3.13) and control of withdrawal symptoms. </p> </section> <section id="CD003409-sec-0080"> <h3 class="title" id="CD003409-sec-0080">Overall completeness and applicability of evidence</h3> <p>The extent to which a Cochrane review can draw conclusions about the effects of an intervention depends on whether the data and results from the included studies are valid. However, systematic reviews should evaluate and take into account not only the internal validity (i.e., the extent to which systematic errors or bias are avoided) of each trial included but also the applicability and generalisability or external validity (i.e., whether the results of a trial can be reasonably applied to a definable group of patients in a particular setting in routine practice) (<a href="./references#CD003409-bbs2-0099" title="DekkersOM , vonElmE , AlgraA , RomijnJA , VandenbrouckeJP . How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology2009;39:89‐94. ">Dekkers 2009</a>). The main threat to external validity comes from the clinical setting, and the social and cultural context in which the studies were conducted, and this is particularly true in the field of addiction, where these contexts can actively affect the overall treatment outcome. </p> <p>In this review, besides the limits in external validity due to the general requirement of RCTs in terms of strict inclusion criteria, highly homogenous study groups, limitations in dose adjustment, etc., the types of participants (adults abusers/dependents on opioids) are quite representative of the general population of opioid dependents. Moreover, the interventions, the settings and the outcomes investigated (completion of treatment, abstinence during the treatment and at follow‐up, adverse events) are important to populations, practitioners and decision makers, and relevant for the context of current practice. </p> <p>However, there are general questions difficult to answer on the basis of our results such as what are the treatment expectations? what defines treatment success? is success strictly limited to suppression of withdrawal symptoms? The studies included did not examine any carried over effects bearing on sustained abstinence or eventual remission of disease and this certanly is a limit. Furthermore onether important limitation to the generalisation of the evidence is the impossibility to cumulate results of very important outcomes such as abstinence at follow‐up and control of withdrawal symptoms due the different ways in which these outcomes are rated and reported in the single studies. Finally 17 out of 22 included trials were conducted in an inpatients' setting, which is probably not the most common setting in clinical practice for this type of intervention, and this could act as an effect modifier in the estimation of efficacy of treatment. </p> </section> <section id="CD003409-sec-0081"> <h3 class="title" id="CD003409-sec-0081">Quality of the evidence</h3> <p>The quality of evidence, assessed according to the GRADE method, may be judged as high for the efficacy of tapered methadone versus any other treatment for the management of opioid withdrawal, see <a href="http://archie.cochrane.org/sections/documents/view?version=54349405397312501521111109100038%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a>. In respect of risk of bias, the quality of evidence was moderate to high, the percentage of included studies judged at low risk of bias were as follow: selection bias 13% for sequence generation and 30% for allocation concealment; performance bias 78%; detection bias 52% and 65% for attrition bias. </p> <p>Finally, the great heterogeneity of the scales used in the primary studies and the way in which results were reported made it not possible to undertake a cumulative analysis. </p> </section> <section id="CD003409-sec-0082"> <h3 class="title" id="CD003409-sec-0082">Potential biases in the review process</h3> <p>None known.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003409-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart of studies" data-id="CD003409-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart of studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003409-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003409-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.1 Completion of treatment." data-id="CD003409-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.1 Completion of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.2 Number of participants abstinent at follow‐up." data-id="CD003409-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tapered methadone versus any other treatment, outcome: 1.2 Number of participants abstinent at follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tapered methadone versus any other treatment, Outcome 1 Completion of treatment." data-id="CD003409-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tapered methadone versus any other treatment, Outcome 1 Completion of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tapered methadone versus any other treatment, Outcome 2 Number of participants abstinent at follow‐up." data-id="CD003409-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tapered methadone versus any other treatment, Outcome 2 Number of participants abstinent at follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tapered methadone versus adrenergic agonists, Outcome 1 Completion of treatment." data-id="CD003409-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tapered methadone versus adrenergic agonists, Outcome 1 Completion of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tapered methadone versus other opioid agonists, Outcome 1 Completion of treatment methadone versus any other opioid agonist." data-id="CD003409-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Tapered methadone versus other opioid agonists, Outcome 1 Completion of treatment methadone versus any other opioid agonist. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Tapered methadone versus other opioid agonists, Outcome 2 Completion of treatment methadone versus buprenorphine." data-id="CD003409-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Tapered methadone versus other opioid agonists, Outcome 2 Completion of treatment methadone versus buprenorphine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tapered methadone versus anxiolytic, Outcome 1 Completion of treatment." data-id="CD003409-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Tapered methadone versus anxiolytic, Outcome 1 Completion of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003409-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/urn:x-wiley:14651858:media:CD003409:CD003409-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_t/tCD003409-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Tapered methadone versus placebo, Outcome 1 Completion of treatment." data-id="CD003409-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Tapered methadone versus placebo, Outcome 1 Completion of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/media/CDSR/CD003409/image_n/nCD003409-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003409-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tapered methadone versus any other treatment for the management of opioid withdrawal</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tapered methadone versus any other treatment for the management of opioid withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with the management of opioid withdrawal <br/> <b>Settings:</b> Inpatient and outpatient <br/> <b>Intervention:</b> Tapered methadone versus any other treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tapered methadone versus any other treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Completion of treatment</b> <br/> Objective <br/> Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.08</b> <br/> (0.97 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1381 <br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>547 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> <br/> (531 to 662) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> <br/> (490 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants abstinent at follow‐up</b> <br/> Objective <br/> Follow‐up: mean 1.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.7 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>386 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕ <br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> <br/> (179 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>262 per 1000</b> <br/> (187 to 366) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tapered methadone versus any other treatment for the management of opioid withdrawal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawal scales</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name of Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Published</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n° items</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n° scores</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>present/absent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptom Checklist (<a href="./references#CD003409-bbs2-0116" title="PowellJ , GrayJA , BradleyBP , KasvikisY , StrangJ , BarrattL , et al. The effects of cue exposure to drug‐related cues in detoxified opiate addicts: a theoretical review and some new data. Addictive Behavior1990;15:339‐54. ">Powell 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective Measures Questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0112" title="HimmelsbachCK . Clinical studies of drug addiction: physical dependence, withdrawal and recovery. Archives of Internal Medicine1942;69:766‐72. ">Himmelsbach 1942</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>List of Withdrawal Symptoms (<a href="./references#CD003409-bbs2-0101" title="GerraG , MarcatoA , CavaccariR , FontanesiB , DelsignoreR , FertonaniG , et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse treatment1995;12:35‐41. ">Gerra 1995</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal Problem Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self Rated Withdrawal Scale (<a href="./references#CD003409-bbs2-0107" title="HaertzenCA , MeketonMJ . Opiate withdrawal measured by the Addiction Research Center Inventory (ARCI). Diseases of the Nervous sSystem1968;29:450‐5. ">Haertzen 1968</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observer rating scale (<a href="./references#CD003409-bbs2-0114" title="KolbL , HimmelsbachCK . Clinical studies of drug addiction III. American journal of Psichiatry1938;94:759‐99. ">Kolb 1938</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short OpioidWithdrawal Scale [German version] (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0011" title="SalehiM , AmanatkarM , BarekatainM . Comparison of the efficacy of methadone and tramadol in opioid‐assisted detoxification. Iranian Journal of Medical Science2007;32(1):28‐31. SalehiM , AmanatkarM , BarekatainM . Tramadol versus methadone for the management of acute opioid withdrawal: An add‐on study. Journal of Research in Medical Sciences2006;11(3):185‐9. ">Salehi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily Abstinence Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>present/absent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Signs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abstinence Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Checklist (<a href="./references#CD003409-bbs2-0117" title="SchubertH , FleischackerW , MeiseV , TheoharC . Preliminary results of guanfacine treatment of acute opiate withdrawal. American Journal of Psichiatry1984;141:1271‐3. ">Schubert 1984</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Checklist (<a href="./references#CD003409-bbs2-0117" title="SchubertH , FleischackerW , MeiseV , TheoharC . Preliminary results of guanfacine treatment of acute opiate withdrawal. American Journal of Psichiatry1984;141:1271‐3. ">Schubert 1984</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Syndrome (<a href="./references#CD003409-bbs2-0098" title="BradleyBP , GossopM , PhillipsGT , LegardaJJ . The development of an Opiate Withdrawal Scale (OWS). British Journal of Addiction1987;82:1139‐42. ">Bradley 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Witdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detoxification Symptom Scale (Fulwiler 1979)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0121" title="WessonDR , LingW . The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs2003;35(2):253‐9. ">Wesson 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Witdrawal Syndrome Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Himmelsbach Drug Withdrawal Symptoms Assessment Chart (<a href="./references#CD003409-bbs2-0111" title="HimmelsbachCK . The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine1941;15:829‐39. ">Himmelsbach 1941</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short Opiate Withdrawal Scale (<a href="./references#CD003409-bbs2-0104" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15:487‐90. ">Gossop 1990</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observer Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0115" title="PeacheyJ , LeiH . Assessment of opioid dependence with naloxone. British Journal of Addictions1988;83:193‐201. ">Peachey 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Opiate Withdrawal Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objective Opioid Withdrawal Scale (<a href="./references#CD003409-bbs2-0109" title="HandelsmanL , CochraneKJ , AronsonM . Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse1987;13:293‐308. ">Handelsman 1987</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawal scales</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus adrenergic agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0001" title="BearnJ , GossopM , StrangJ . Randomised double‐blind comparison of lofexidine and methadone in the in‐patient treatment of opiate withdrawal. Drug and Alcohol Dependence1996;43(1‐2):87‐91. ">Bearn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean scores higher for (1) on days 13‐21 and for (2) days 2‐12. Peak score on (1) day 13 and (2) day 10. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2) 2 both female, experienced dizziness due to postural hypotension.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0003" title="CamiJ , DeTorresS , SanL , SoleA , GuerraD , UgenaB . Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics1985;38(3):336‐41. ">Camí 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscular aching, flatulence and drowsiness more common in (1). Sleep disturbance &amp; weeping in (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 of (2) had transferred loss of consciousness. (2) 4 (1) 1 experienced orthostatic hypotension. A graph shows a steady decline and similar magnitude in both groups regarding adverse effects, from days 1 to 6. After day 6, the scores for (1) increased, while in (2) continued to decline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0004" title="DaweS , GrayJA . Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug and Alcohol Dependence1995;39(3):207‐12. ">Dawe 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimum withdrawal scores, mean (1) 25 (2) 33; maximum (1) 69 (2) 53. Time points minimum (1) day 1 (2) day 7, maximum (1) day 10 (2) day 2/3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0006" title="GerraG , ZaimovicA , RustichelliP , FontanesiB , ZambelliU , TimpanoM , et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment2000;18(2):185‐91. ">Gerra 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In (2) mean scores slightly lower but not significantly lower than (3). During the last 4 days of treatment and after the first 4 days after methadone discontinuation; (1) mean scores significantly higher (2) than (3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily blood pressure only for (2) &amp; (3): no significant differences at any point. (2) 3 (3) 2 experienced side effects necessitate dose reduction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0007" title="HowellsC , AllenS , GuptaJ , StillwellG , MarsdenJ , FarrelM . Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence2002;67:169‐76. ">Howells 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lowest daily score: mean (1) 49.4 (2) 50.0 ; Highest daily score: mean (1) 67.6 (2) 69.3; Total mean (1) 572.1 (2) 596.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sitting blood pressure in (2) 4/32 lowest 61 mmHg, in (1) 3/36 lowest 80 mmHg, NS Depressive symptoms in 2 patients, one in each treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0008" title="JiangZ . Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy vs methadone. Chinese Journal of Neurology and Psychiatry1993;26(1):10‐3. ">Jiang 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>On day 1 no significant differences in the two groups, between days 2 and 4 higher in (2), between days 8 and 12 lower in (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The scores higher in (2) compared to (1) from days 1 to 7, the greatest difference occurred on day 2 of treatment when the mean side effects scores was (1) 1.9 and (2) 8.2. The score subsequently declined in both groups. Comparison of each undesirable side effect suggests that general tiredness, weakness in walking, dizziness in standing position, dry mouth and lethargy are most common occurrences in (2), while in (1) only a small numbers of patients experienced general tiredness, weakness in walking, dry mouth and lethargy . In (2) 89 experienced dizziness on standing, mostly in the second and third days of treatment. Anxiety scores were significantly lower in (2) by day 11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0009" title="KleberHD , RiordanCE , RounsavilleB , KostenT , CharneyD , GaspariJ , et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry1985;42(4):391‐4. KostenRT , RounsavilleJ , KleberHD . Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry1984;25(5):503‐8. KostenTR , RounsavilleBJ , KleberHD . Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse1985;11(1‐2):1‐10. RounsavilleBJ , KostenT , KleberH . Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease1985;173(2):103‐10. ">Kleber 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean withdrawal scores at baseline and weeks 1‐2‐3‐4: at baseline no differences, during the first 2 weeks (1) 7.6, (2) 19.0, during the second two weeks (1) 13,0 (2) 12,0 ; Rates of withdrawal symptoms: (2) higher than (1); Comparison of withdrawal characteristics of success and failure in the groups were not statistically different. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of side effects, rated by physicians and nurses: (1) 11,5 (2) 16,8. Characteristics of side effects: for the majority of symptoms there were no differences among the two groups. Number using sleep medications: (1) 70% (2) 63%; Scores of Beck Depression Inventory between successfully drug‐free or not patients in the 2 groups were respectively: 54% and 17%. For the same groups, the percentage above the median for each ASI area were as follows: for medical area 62% and 46%, for employment 50% and 22%, for legal 35% and 22% , for family/social 31% and 28%, for psychological 31% and 28%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0012" title="SanL , CamìJ , PeriJM , MataR , PortaM . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction1990;85(1):141‐7. SanL , CamìJ , PeriJM , MataR , PortaM . Success and Failure at inpatient heroin detoxification. British Journal of Addiction1989;84(1):81‐7. ">San 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (graph): Significant differences between (1) and (2) on days 2, 3, 4 and 5, higher in (1); between (1) and (3) on days 2, 3, 4 and 11, higher in (3); no significant differences between (2) and (3); the maximum mean was (1) 4.9, (2) 8.1, (3) 7.6 all on day 2. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotensive effect more intense in (2); changes in heart rate more pronounced in (2) than in (3); (1) and (3) most frequent side effects: asthenia, dry mouth, flushing, mental clouding, thirst. . Differences in personality tests and patient's mood: NS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0014" title="SanL , FernandezT , CamìJ , GossopM . Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment1994;11(5):463‐9. ">San 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (graph): from day 9 higher in (2) and (3) for three days and in (1) after day 11, statistically significant between (1) and (3) on days 10,11 higher in (3); and between (1) and (2) on days 11,15, higher in (1); on day 20 higher in (3) compared with (1) and (2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differences in blood pressure and heart rate: for blood pressure, in (3) after day 13 grater decrease than in (1) and (2); for heart rate, in (3) bradycardia from day 9 with lowest rate on day 11, (62 beats per min); statistical significant difference between (3) compared with (1) and (2) in days 9, 10,11, 12,16, 17, 18, 19. Differences in personality tests and patient's mood: NS. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean withdrawal scores at baseline, after the first dose of medication and during the treatment no significant differences in the magnitude of the decrease in withdrawal between the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 patients in (3) had to withdraw from the study because of decreased systolic blood pressure (&lt; 90 mmHg) and bradycardia (HR &lt; 50 BPM) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0020" title="WashtonAM , ResnickRB . Clonidine versus methadone for opiate detoxification. Lancet1980;2(8207):1297. WashtonAM , ResnickRB . Clonidine vs methadone for opiate detoxification: double‐blind outpatient trials. In: HarrisLS editor(s). NIDA Research Monograph. Vol. 34, Washington DC: Department of Health and Human Services, 1981:89‐94. ">Washton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major symptomatic complaints, specifically lethargy, restlessness and insomnia were identical for both groups. The main items contributing to scores in both groups were sleep problems, anxiety/nervousness, irritability, lack of energy, aches/pains and feeling cold. (2) reported symptoms during the 1° week of the study whereas (1) in the last week. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy and sluggishness most consistent complaints in (2).</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus adrenergic agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus other opioid agonists</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0010" title="Madlung‐KratzerE , SpitzerB , BroschR , DunkelD , HaringC . A double‐blind, randomised, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification. Addiction2009; Vol. 104, issue 9:1549‐57. ">Madlung‐Kratzer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Changes in signs and symptoms of opioid withdrawal [12‐item German version of the Short Opioid Withdrawal Scale] assessed on days 0, 3, 7, 10, 14, 18 and 22 by patient self‐rating. </p> <p>At study entry signs and symptoms of withdrawal were mild but deteriorated steadily over time (day 0 versus day 22, P &lt; 0.001). The only difference between the groups was found on day 18 (P = 0.022). All symptoms showed a homogeneous pattern of changes. (1) day 0 8.15 6.48 (7.00), day 22 16.00 7.81(15.00) P &lt; 0.001; (2) day 0: 8.07 6.09 (7.00) day 22:18.32 8.98 (18.00) P &lt; 0.001 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of adverse events was low; 16 (16%) patients in the SRM group and 13 (13%) patients in the methadone group experienced at least one adverse event (c2 test, P = 0.586). Thirty of 45 (67%) of all adverse events were rated as being unrelated, nine (20%) as possibly related (SRM: six patients; methadone: three patients) and one (2%) (methadone group) as probably related to the study drug. The majority of adverse events (23 of 45) were gastrointestinal system disorders, such as <br/> nausea (three), vomiting (10), dentalgia (five), followed by psychiatric disorders (seven of 45, e.g. dysphoria, agitation, depression, panic attacks). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0015" title="SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , OhlmeirM , PassieT , et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology2005;10(2):157‐64. SeifertJ , MetznerC , PaetzoldW , BorsutzkyM , PassleT , RollnikJ , et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry2002;35:159‐64. ">Seifert 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOWS score (days 0‐2): no differences; weeks 1‐2 (2) fewer symptoms than (1); no differences in self‐rating scales </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0016" title="SorensenJL , HargreavesWA , WeinbergJA . Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Archives of General Psychiatry1982;39(2):167‐71. ">Sorensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean symptom discomfort index initially declined then increased with drug taper. Initial, stabilisation and final ratings by graph: (1)18, 10, 15 (2) 16, 7, 16. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 overdose incident, possibly due to combination with alcohol.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0017" title="SteinmannC , ArtmannS , HennebergB , PaulHW . Should methadone or buprenorphine be preferred for opiate detoxification?: [Methadon‐Racemat versus Buprenorphin zur stationären Entgiftungsbehandlung Opiatabhängiger]. Psychiatrische Praxis2007;34(S1):103‐5. SteinmannC , ArtmannS , SchachtschneiderA , PaulHW . Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht2008;54(4):217‐21. ">Steinmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results in favour of buprenorphine only in the first day of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not assessed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0018" title="TennantSJr , RusselBA , CasasSK , BleickRN . Heroin detoxification. A comparison of propoxyphene and methadone. JAMA1975;232(10):1019‐23. ">Tennant 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean daily withdrawal scores (1) 6.6 (2) 9.6. Difference significant on days 8, 12, 15, 16, 17. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one statistically significant difference. (1)6 [16.7%], (2)17 [47%] reported euphoria. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0019" title="UmbrichtA , HooverDR , TuckerMJ , LeslieJM , ChaissonRE , PrestonKL . Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin dependent patients with HIV infection. Drug and Alcohol Dependence2003;69:263‐72. ">Umbricht 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant and observer rating scales: after first‐dose effect, further improvements were minimal, and overall mean scores during treatment were not significantly lower than scores after one treatment dose. The overall mean time averaged decreases ranged from‐5.1 to ‐6.0 for OOWS and ‐3.3 to ‐4.7 for SOWS. No significant differences in the magnitude of the decrease in the withdrawal between the treatment groups. At no time during treatment did withdrawal scores exceed baseline scores for any individual. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No major changes in blood pressure or heart rate during the observation time interval of the study. There was a trend (P = 0.06) toward myosis in the buprenorphine and methadone groups, consistent with a pharmacologic effect of treatment. Systolic blood pressure decreased significantly in the buprenorphine group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003409-bbs2-0023" title="ZarghamiM , MasoumB , ShiranMR . Tramadol versus methadone for treatment of opiate withdrawal: a double blind, randomised, clinical trial. Journal of Addictive Diseases2012;31:112‐7. ">Zarghami 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statistical analysis revealed that significant decreases (P ≤ .04) were found in the OOWS scores in both treatment methods up to day 14; no statistically significant difference was found between OOWS scores of the treatment methods at different intervals (P ≥ .1), except for day 6 of the study (P = .03) where results were in favour of tramadol. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant differences were observed in side effects scores for dizziness, somnolence, ataxia, constipation, nausea, seizures, and respiratory depression between two treatment methods, except for perspiration and pain, which were significantly higher in tramadol (P = .02) and methadone (P = 0.01) treatment methods, respectively </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>OOWS: Objective Opioid Withdrawal Scale; SOWS: Short Opioid Withdrawal Scale</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus other opioid agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus anxiolytics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective and Objective withdrawal scale: no significant differences between methadone and buspirone doses </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0005" title="DrummondDC , TurkingtonD , RahmanMZ , MullinPJ , JacksonP . Chlordiazepoxide versus Methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence1989;23(1):63‐71. ">Drummond 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant higher scores in the chlordiazepoxide group only on day 3; at the end of the study, the scores were higher in the methadone group but not statistically significant. Analysis of individual items in the OWS (Opiate Withdrawal Scale) failed to implicate any particular item as being responsible for the difference between the two groups. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In methadone group relative bradycardia is more present in the first days of treatment and the difference with respect to the chlordiazepoxide group became statistically significant on days 4 and 7. As methadone was gradually withdrawn, the mean heart rate returned to a level comparable to the beginning period. Mean pupil size was less in methadone group during the treatment period and the difference was statistically significant on day 5, similarly mean temperature was lower in this group on day 3. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus anxiolytics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0002" title="Buydens‐BrancheyL , BrancheyM , Reel‐BranderC . Efficacy of buspirone in the treatment of opioid withdrawal. Journal of Clinical Psychopharmacology2005;25(3):230‐6. ">Buydens‐Branchey 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective and Objective scales: symptoms in placebo group were significantly more pronounced </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0013" title="SanL , CamìJ , FernandezT , OlleJM , PeriJM , TorrensM . Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction1992;87(1):55‐62. ">San 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores in the placebo groups, with the most severe symptoms on day 1 to 15. 8/11 placebo‐treated patients needed to be switched from placebo to methadone because the OWC (Opiate Withdrawal Checklist) daily score was &gt; 15. With respect to features of the withdrawal syndrome in placebo patients, two stages were observed: anxiety, chills, gooseflesh, myalgia and weakness were the most common on day 1 to 5 and sleep disturbance persisted on day 6 to 13. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003409-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus paiduyangsheng</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Side effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003409-bbs2-0022" title="YangL , ChenJ , LiL , WenP , ZhangX . Controlled clinical study on Paiduyangsheng capsule in detoxification of heroin abuse. Chinese Journal of Drug Abuse Prevention2006;12(2):86‐8. ">Yang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Withdrawal symptoms and side effects methadone versus paiduyangsheng</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/full#CD003409-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003409-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tapered methadone versus any other treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Completion of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.97, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants abstinent at follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tapered methadone versus any other treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003409-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tapered methadone versus adrenergic agonists</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Completion of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.91, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tapered methadone versus adrenergic agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003409-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tapered methadone versus other opioid agonists</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Completion of treatment methadone versus any other opioid agonist <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.89, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Completion of treatment methadone versus buprenorphine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.69, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tapered methadone versus other opioid agonists</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003409-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tapered methadone versus anxiolytic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Completion of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.47, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tapered methadone versus anxiolytic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003409-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tapered methadone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Completion of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.21, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Tapered methadone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003409.pub4/references#CD003409-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003409.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003409-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003409-note-0005">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003409\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003409\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003409\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003409\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003409.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003409.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003409.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003409.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003409.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718494478"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003409.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718494482"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003409.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd1b6294cf401',t:'MTc0MDcxODQ5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 